The Advisory Committee on Immunization Practices (ACIP) suggestions have been up to date for the meningococcal serogroup B MenB-4C vaccine (Bexsero), in accordance with the up to date U.S. Meals and Drug Administration label. The up to date suggestions have been printed within the Dec. 12 challenge of the U.S. Facilities for Illness Management and Prevention Morbidity and Mortality Weekly Report.
Sarah Schillie, M.D., from the CDC in Atlanta, and colleagues current the up to date suggestions of the ACIP for the Bexsero MenB-4C Vaccine.
Primarily based on new immunogenicity information, the FDA modified the label for the Bexsero MenB-4C vaccine from a two-dose schedule at intervals of zero and at the very least one month to a two-dose schedule at intervals of zero and 6 months, and added a three-dose schedule (zero, one to 2, and 6 months) in August 2024.
The authors notice that ACIP voted to replace its suggestions for the MenB-4C dosing interval and schedule to align with the brand new FDA label on Oct. 24, 2024.
For wholesome adolescents and younger adults aged 16 to 23 years, ACIP recommends extending the interval for the two-dose collection from zero and at the very least one month to zero and 6 months, primarily based on shared medical decision-making, and added a suggestion for the three-dose collection for these aged 10 years and older at elevated threat. The up to date suggestions align with these of the opposite FDA-licensed meningococcal serogroup B vaccine, MenB-FHbp (Trumenba).
“These changes were prompted by new immunogenicity data and were not due to safety concerns,” the authors write. “This report only updates recommendations for the dosing interval and schedule for MenB-4C; other previously published meningococcal vaccination guidance remains unchanged.”
Extra info:
Sarah Schillie et al, New Dosing Interval and Schedule for the Bexsero MenB-4C Vaccine: Up to date Suggestions of the Advisory Committee on Immunization Practices—United States, October 2024, MMWR. Morbidity and Mortality Weekly Report (2024). DOI: 10.15585/mmwr.mm7349a3
Quotation:
ACIP updates suggestions for Bexsero MenB-4C vaccine (2024, December 13)
retrieved 13 December 2024
from https://medicalxpress.com/information/2024-12-acip-bexsero-menb-4c-vaccine.html
This doc is topic to copyright. Aside from any honest dealing for the aim of personal research or analysis, no
half could also be reproduced with out the written permission. The content material is offered for info functions solely.
